Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 496 to 510 of 1833 results for carers

  1. Benegrastim for treating chemotherapy-induced neutropenia in people with breast cancer [TSID11769]

    Awaiting development Reference number: GID-TA11088 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Preferred place of care and place of death:- When planning and managing end of life care, what factors help children and young people with life-limiting conditions and their parents or carers to decide where they would like end of life care to be provided and where they prefer to die?

    children and young people with life-limiting conditions and their parents or carers to decide where they would like end of life care to...

    Research recommendation
    Published
    15 February 2017

  3. Secondary bacterial infection of eczema and other common skin conditions: antimicrobial prescribing (NG190)

    This guideline sets out an antimicrobial prescribing strategy for secondary bacterial infection of eczema and covers infection of other common skin conditions. It aims to optimise antibiotic use and reduce antibiotic resistance. The recommendations are for adults, young people and children aged 72 hours and over. They do not cover diagnosis.

    Antimicrobial prescribing guideline
    Published
    2 March 2021
    View recommendations

    Sections for NG190

  4. Interventional Correction of Superior Sinus Venosus Defect and Partial Anomalous Pulmonary Venous Drainage

    Awaiting development Reference number: GID-IPG10419 Expected publication date: TBC

    Interventional procedures guidance
    Awaiting development

  5. Guide to the methods of technology appraisal 2013 (PMG9)

    This guide provides an overview of the principles and methods of health technology assessment and appraisal within the context of the NICE appraisal process

  6. Human acellular vessel (Humacyl; HAV) For use as an arterial venous access for patients with end stage renal disease (ESRD) requiring haemodialysis [ID3747]

    Awaiting development Reference number: GID-TA11404 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Marstacimab for treating severe haemophilia A or B in people 12 years and over with inhibitors to factor-replacement therapy [TSID12143]

    Awaiting development Reference number: GID-TA11691 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Percutaneous insertion of a temporary heart pump for left ventricular haemodynamic support in high-risk percutaneous coronary interventions

    Awaiting development Reference number: GID-IPG10409 Expected publication date: TBC

    Interventional procedures guidance
    Awaiting development

  9. Transvaginal Ultrasound-Guided Radiofrequency Ablation (RFA) for Uterine Fibroids

    Awaiting development Reference number: GID-IPG10465 Expected publication date: TBC

    Interventional procedures guidance
    Awaiting development

  10. Mavorixafor for treating WHIM syndrome [ID3946]

    Awaiting development Reference number: GID-TA10833 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Subcutaneous mosunetuzumab for treating relapsed or refractory follicular lymphoma after 2 or more treatments TSID 12081

    Awaiting development Reference number: GID-TA11705 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Extravascular implantable cardioverter defibrillator insertion for preventing sudden cardiac death

    Awaiting development Reference number: GID-IPG10437 Expected publication date: TBC

    Interventional procedures guidance
    Awaiting development

  13. Blarcamesine for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [TSID12157]

    Awaiting development Reference number: GID-TA11717 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Elinzanetant for treating vasomotor symptoms caused by adjuvant endocrine treatment to prevent or treat hormone-receptor positive breast cancer [ID6544]

    Awaiting development Reference number: GID-TA11720 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Elamipretide for treating Barth syndrome in people of any age [ID6545]

    Awaiting development Reference number: GID-TA11719 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development